The chemistry of bioconjugation in nanoparticles-based drug delivery system

Advances in Condensed Matter Physics

Volumn 2015, Issue , 2015, Pages

  Werengowska Ciećwierz, Karolina ^a   Wis̈niewski, Marek ^a,b   Terzyk, Artur P ^a   Furmaniak, Sylwester ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b INVEST TECH RandD Center   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84924363723     PISSN: 16878108     EISSN: 16878124     Source Type: Journal    
DOI: 10.1155/2015/198175     Document Type: Review

References (199)

1. R. A. Freitas Jr., "What is nanomedicine?" Nanomedicine, vol. 1, no. 1, pp. 2-9, 2005.
2. B. Mishra, B. B. Patel, and S. Tiwari, "Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery", Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 6, no. 1, pp. 9-24, 2010.
3. S. K. Sahoo, S. Parveen, and J. J. Panda, "The present and future of nanotechnology in human health care", Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 3, no. 1, pp. 20-31, 2007.
4. R. A. Freitas Jr., "What is nanomedicine?" Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 1, no. 1, pp. 2-9, 2005.
5. K. Kostarelos, "The emergence of nanomedicine: a field in the making", Nanomedicine, vol. 1, no. 1, pp. 1-3, 2006.
6. C. Wang, S. Ravi, G. V. Martinez et al., "Dual-purposemagnetic micelles for MRI and gene delivery", Journal of Controlled Release, vol. 163, no. 1, pp. 82-92, 2012.
7. R. G. Mendes, A. Bachmatiuk, B. Büchner, G. Cuniberti, and M. H. Rümmeli, "Carbon nanostructures as multi-functional drug delivery platforms", Journal of Materials Chemistry B, vol. 1, no. 4, pp. 401-428, 2013.
8. C. Wei, "The valuable and significant role of Nanomedicine", Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 1, no. 4, p. 285, 2005.
9. O. M. Koo, I. Rubinstein, and H. Onyuksel, "Role of nanotechnology in targeted drug delivery and imaging: a concise review", Nanomedicine, vol. 1, no. 3, pp. 193-212, 2005.
10. T. Flynn and C. Wei, "The pathway to commercialization for nanomedicine", Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 1, no. 1, pp. 47-51, 2005.
11. N. Bertrand, J. Wu, X. Xu, N. Kamaly, and O. C. Farokhzad, "Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology", Advanced Drug Delivery Reviews, vol. 66, pp. 2-25, 2014.
12. Y. Liu, H. Miyoshi, and M. Nakamura, "Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles", International Journal of Cancer, vol. 120, no. 12, pp. 2527-2537, 2007.
13. N. K. Mehra, V. Mishra, and N. K. Jain, "A review of ligand tethered surface engineered carbon nanotubes", Biomaterials, vol. 35, no. 4, pp. 1267-1283, 2014.
14. V. P. Torchilin, "Multifunctional nanocarriers", Advanced Drug Delivery Reviews, vol. 58, no. 14, pp. 1532-1555, 2006.
15. S. Parveen, R. Misra, and S. K. Sahoo, "Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging", Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 8, no. 2, pp. 147-166, 2012.
16. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni, "Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity", Pharmacological Reviews, vol. 56, no. 2, pp. 185-229, 2004.
17. J. Verweij, M. Clavel, and B. Chevalier, "Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind", Annals of Oncology, vol. 5, no. 6, pp. 495-505, 1994.
18. C. Samorì, H. Ali-Boucetta, R. Sainz et al., "Enhanced anticancer activity of multi-walled carbon nanotube-methotrexate conjugates using cleavable linkers", Chemical Communications, vol. 46, no. 9, pp. 1494-1496, 2010.
19. Y. Ren and G. Pastorin, "Incorporation of hexamethylmelamine inside capped carbon nanotubes", Advanced Materials, vol. 20, no. 11, pp. 2031-2036, 2008.
20. S. Aryal, C.-M. J. Hu, and L. Zhang, "Combinatorial drug conjugation enables nanoparticle dual-drug delivery", Small, vol. 6, no. 13, pp. 1442-1448, 2010.
21. H. S. Oberoi, N. V. Nukolova, A. V. Kabanov, and T. K. Bronich, "Nanocarriers for delivery of platinum anticancer drugs", Advanced Drug Delivery Reviews, vol. 65, no. 13-14, pp. 1667-1685, 2013.
22. G. Cirillo, S. Hampel, U. G. Spizzirri, O. I. Parisi, N. Picci, and F. Iemma, "Carbon nanotubes hybrid hydrogels in drug delivery: a perspective review", BioMed Research International, vol. 2014, Article ID 825017, 17 pages, 2014.
23. M. Zhang and M. Yudasaka, "Potential application of nanocarbons as a drug delivery system", Carbon, vol. 69, p. 642, 2014.
24. G. A. Hughes, "Nanostructure-mediated drug delivery", Nanomedicine, vol. 1, no. 1, pp. 22-30, 2005.
25. B. Wilson, M. K. Samanta, K. Santhi, K. P. S. Kumar, M. Ramasamy, and B. Suresh, "Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine", Nanomedicine, vol. 6, no. 1, pp. e144-e152, 2010.
26. K. Y. Kim, "Nanotechnology platforms and physiological challenges for cancer therapeutics", Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 3, no. 2, pp. 103-110, 2007.
27. R. Chouhan and A. K. Bajpai, "Release dynamics of ciprofloxacin from swellable nanocarriers of poly (2-hydroxyethyl methacrylate): an in vitro study", Nanomedicine, vol. 6, no. 3, pp. 453-462, 2010.
28. E. Koren, A. Apte, A. Jani, and V. P. Torchilin, "Multifunctional PEGylated 2C5-immunoliposomes containing pHsensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity", Journal of Controlled Release, vol. 160, no. 2, pp. 264-273, 2012.
29. A. Koshkaryev, A. Piroyan, and V. P. Torchilin, "Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes", Cancer Biology and Therapy, vol. 13, no. 1, pp. 50-60, 2012.
30. A. Etzerodt, M. B. Maniecki, J. H. Graversen, H. J. Moller, V. P. Torchilin, and S. K. Moestrup, "Efficient intracellular drugtargeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163", Journal of Controlled Release, vol. 160, no. 1, pp. 72-80, 2012.
31. K. W. Kang, M.-K. Chun, O. Kim et al., "Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy", Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 6, no. 2, pp. 210-213, 2010.
32. U. Kedar, P. Phutane, S. Shidhaye, and V. Kadam, "Advances in polymeric micelles for drug delivery and tumor targeting", Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 6, no. 6, pp. 714-729, 2010.
33. P. Arukuusk, L. Pärnaste, N. Oskolkov et al., "New generation of efficient peptide-based vectors, NickFects, for the delivery of nucleic acids", Biochimica et Biophysica Acta, vol. 1828, no. 5, pp. 1365-1373, 2013.
34. Y. Wu, P. Sadatmousavi, R. Wang, S. Lu, Y.-F. Yuan, and P. Chen, "Self-assembling peptide-based nanoparticles enhance anticancer effect of ellipticine in vitro and in vivo", International Journal of Nanomedicine, vol. 7, pp. 3221-3233, 2012.
35. L. Crombez, M. C. Morris, S. Deshayes, F. Heitz, and G. Divita, "Peptide-based nanoparticle for ex vivo and in vivo dug delivery", Current Pharmaceutical Design, vol. 14, no. 34, pp. 3656-3665, 2008.
36. A. N. Shirazi, R. Tiwari, B. S. Chhikara, D. Mandal, and K. Parang, "Design and biological evaluation of cell-penetrating peptide-doxorubicin conjugates as prodrugs", Molecular Pharmaceutics, vol. 10, no. 2, pp. 488-499, 2013.
37. S. Deshayes, K. Konate, A. Rydström et al., "Self-assembling peptide-based nanoparticles for siRNA delivery in primary cell lines", Small, vol. 8, no. 14, pp. 2184-2188, 2012.
38. K. K. Hou, H. Pan, G. M. Lanza, and S. A. Wickline, "Melittin derived peptides for nanoparticle based siRNA transfection", Biomaterials, vol. 34, no. 12, pp. 3110-3119, 2013.
39. C. P. Reis, R. J. Neufeld, A. J. Ribeiro, and F. Veiga, "Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles", Nanomedicine, vol. 2, no. 1, pp. 8-21, 2006.
40. N. Mody, R. K. Tekade, N. K. Mehra, P. Chopdey, and N. K. Jain, "Dendrimer, liposomes, carbon nanotubes and PLGA nanoparticles: one platform assessment of drug delivery potential", AAPS PharmSciTech, vol. 15, no. 2, pp. 388-399, 2014.
41. U. Gupta, H. B. Agashe, A. Asthana, and N. K. Jain, "Dendrimers: novel polymeric nanoarchitectures for solubility enhancement", Nanomedicine, vol. 2, no. 2, pp. 66-73, 2006.
42. S. Wen, H. Liu, H. Cai, M. Shen, and X. Shi, "Targeted and pH-responsive delivery of doxorubicin to cancer cells using multifunctional dendrimer-modifiedmulti-walled carbon nanotubes", Advanced Healthcare Materials, vol. 2, no. 9, pp. 1267-1276, 2013.
43. M. Foldvari and M. Bagonluri, "Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues", Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 4, no. 3, pp. 183-200, 2008.
44. A. Shahi, "Carbon nanotubes: a noval carrier system for drug delivery and cancer therapy", International Journal of Pharma and Bio Sciences, vol. 5, no. 3, pp. 298-306, 2014.
45. C. P. Firme III and P. R. Bandaru, "Toxicity issues in the application of carbon nanotubes to biological systems", Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 6, no. 2, pp. 245-256, 2010.
46. J. Y. Hwang, U. S. Shin, W. C. Jang, J. K. Hyun, I. B. Wall, and H. W. Kim, "Biofunctionalized carbon nanotubes in neural regeneration: a mini-review", Nanoscale, vol. 5, no. 2, pp. 487-497, 2013.
47. H. J. Zhang, C. Chen, L. Hou et al., "Targeting and hyperthermia of doxorubicin by the delivery of single-walled carbon nanotubes to EC-109 cells", Journal of Drug Targeting, vol. 21, no. 3, pp. 312-319, 2013.
48. Z. Liu, K. Chen, C. Davis et al., "Drug delivery with carbon nanotubes for in vivo cancer treatment", Cancer Research, vol. 68, no. 16, pp. 6652-6660, 2008.
49. Z. Liu, A. C. Fan, K. Rakhra et al., "Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy", Angewandte Chemie, vol. 48, no. 41, pp. 7668-7672, 2009.
50. N. W. S. Kam and H. Dai, "Single walled carbon nanotubes for transport and delivery of biological cargos", Physica Status Solidi B, vol. 243, no. 13, pp. 3561-3566, 2006.
51. N. W. S. Kam, M. O'Connell, J. A. Wisdom, and H. Dai, "Carbon nanotubes as multifunctional biological transporters and nearinfrared agents for selective cancer cell destruction", Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 33, pp. 11600-11605, 2005.
52. N. W. S. Kam, T. C. Jessop, P. A. Wender, and H. Dai, "Nanotube molecular transporters: internalization of carbon nanotube-protein conjugates into mammalian cells", Journal of the American Chemical Society, vol. 126, no. 22, pp. 6850-6851, 2004.
53. Z. Liu, S. Tabakman, K. Welsher, and H. Dai, "Carbon nanotubes in biology and medicine: in vitro and in vivo detection, imaging and drug delivery", Nano Research, vol. 2, no. 2, pp. 85-120, 2009.
54. Z. Liu, S. M. Tabakman, Z. Chen, and H. Dai, "Preparation of carbon nanotube bioconjugates for biomedical applications", Nature Protocols, vol. 4, no. 9, pp. 1372-1382, 2009.
55. A. K. Jain, V. Dubey, N. K. Mehra et al., "Carbohydrateconjugated multiwalled carbon nanotubes: development and characterization", Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 5, no. 4, pp. 432-442, 2009.
56. X. Ma, C. Shu, J. Guo et al., "Targeted cancer therapy based on single-wall carbon nanohorns with doxorubicin in vitro and in vivo", Journal of Nanoparticle Research, vol. 16, no. 7, article 2497, 2014.
57. S. Han, T. Xia, Q. Li, J. Guo, and P. Lu, "Application of functional quantum dots in cancer diagnosis and therapy: a review", Chinese Journal of Biotechnology, vol. 29, no. 1, pp. 10-20, 2013.
58. R. Lehner, X. Wang, S. Marsch, and P. Hunziker, "Intelligent nanomaterials for medicine: carrier platforms and targeting strategies in the context of clinical application", Nanomedicine, vol. 9, no. 6, pp. 742-757, 2013.
59. H. Hosseinzadeh, F. Atyabi, R. Dinarvand, and S. N. Ostad, "Chitosan-Pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study", International Journal of Nanomedicine, vol. 7, pp. 1851-1863, 2012.
60. S. Danson, D. Ferry, V. Alakhov et al., "Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer", British Journal of Cancer, vol. 90, no. 11, pp. 2085-2091, 2004.
61. W. X. Mai and H. Meng, "Mesoporous silica nanoparticles: a multifunctional nano therapeutic system", Integrative Biology, vol. 5, no. 1, pp. 19-28, 2013.
62. Q. Zhang, F. Liu, K. T. Nguyen et al., "Multifunctional mesoporous silica nanoparticles for cancer-targeted and controlled drug delivery", Advanced Functional Materials, vol. 22, no. 24, pp. 5144-5156, 2012.
63. W. He, Y. Lu, J. Qi, L. Chen, F. Hu, and W. Wu, "Nanoemulsiontemplated shell-crosslinked nanocapsules as drug delivery systems", International Journal of Pharmaceutics, vol. 445, no. 1-2, pp. 69-78, 2013.
64. B. Brime, P. Frutos, P. Bringas, A. Nieto, M. P. Ballesteros, and G. Frutos, "Comparative pharmacokinetics and safety of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and amphotericin B deoxycholate in animal models", Journal of Antimicrobial Chemotherapy, vol. 52, no. 1, pp. 103-109, 2003.
65. E. Che, X. Zheng, C. Sun, D. Chang, T. Jiang, and S. Wang, "Drug nanocrystals: a state of the art formulation strategy for preparing the poorly water-soluble drugs", Asian Journal of Pharmaceutical Sciences, vol. 7, no. 2, pp. 85-95, 2012.
66. O. Kayser, C. Olbrich, V. Yardley, A. F. Kiderlen, and S. L. Croft, "Formulation of amphotericin B as nanosuspension for oral administration", International Journal of Pharmaceutics, vol. 254, no. 1, pp. 73-75, 2003.
67. I. Roy, T. Y. Ohulchanskyy, H. E. Pudavar et al., "Ceramicbased nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy", Journal of the American Chemical Society, vol. 125, no. 26, pp. 7860-7865, 2003.
68. I. Altintas, R. Heukers, R. Van Der Meel et al., "Nanobodyalbumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells", Journal of Controlled Release, vol. 165, no. 2, pp. 110-118, 2013.
69. H. Wartlick, B. Spänkuch-Schmitt, K. Strebhardt, J. Kreuter, and K. Langer, "Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles", Journal of Controlled Release, vol. 96, no. 3, pp. 483-495, 2004.
70. W. Wu, J. Shen, Z. Gai, K. Hong, P. Banerjee, and S. Zhou, "Multi-functional core-shell hybrid nanogels for pH-dependent magnetic manipulation, fluorescent pH-sensing, and drug delivery", Biomaterials, vol. 32, no. 36, pp. 9876-9887, 2011.
71. S. V. Vinogradov, E. V. Batrakova, and A. V. Kabanov, "Nanogels for oligonucleotide delivery to the brain", Bioconjugate Chemistry, vol. 15, no. 1, pp. 50-60, 2004.
72. S. Y. Wang, M. C. Liu, and K. A. Kang, "Magnetic nanoparticles and thermally responsive polymer for targeted hyperthermia and sustained anti-cancer drug delivery", Advances in Experimental Medicine and Biology, vol. 765, pp. 315-321, 2013.
73. B. A. Moffat, G. Ramachandra Ready, P. McConville et al., "A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI", Molecular Imaging, vol. 2, no. 4, pp. 324-332, 2003.
74. D. M. Yuan, Y. L. Lv, Y. W. Yao et al., "Efficacy and safety of Abraxane in treatment of progressive and recurrent non-small cell lung cancer patients: a retrospective clinical study", Thoracic Cancer, vol. 3, no. 4, pp. 341-347, 2012.
75. Z. Yan, L. Xia, H. Qiu, P. Chen, and B. Zhang, "Short-term outcomes of albumin-bound paclitaxel (abraxane)-containing chemotherapy in patients with advanced gastric cancer: a report of 14 cases", The Chinese-German Journal of Clinical Oncology, vol. 12, no. 1, pp. 30-34, 2013.
76. P. K. Paik, L. P. James, G. J. Riely et al., "A phase 2 study of weekly albumin-bound paclitaxel (Abraxane) given as a twohour infusion", Cancer Chemotherapy and Pharmacology, vol. 68, no. 5, pp. 1331-1337, 2011.
77. G. H. Hermanson, Bioconjugate Techniques, Academic Press, San Diego, Calif, USA, 2nd edition, 2008.
78. L. Nobs, F. Buchegger, R. Gurny, and E. Allémann, "Current methods for attaching targeting ligands to liposomes and nanoparticles", Journal of Pharmaceutical Sciences, vol. 93, no. 8, pp. 1980-1992, 2004.
79. P. Kocbek, N. Obermajer, M. Cegnar, J. Kos, and J. Kristl, "Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody", Journal of Controlled Release, vol. 120, no. 1-2, pp. 18-26, 2007.
80. O. Ishida, K. Maruyama, H. Tanahashi et al., "Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo", Pharmaceutical Research, vol. 18, no. 7, pp. 1042-1048, 2001.
81. K. Maruyama, T. Takizawa, T. Yuda, S. J. Kennel, L. Huang, and M. Iwatsuru, "Targetability of novel immunoliposomes modified with amphipathic poly (ethylene glycol) s conjugated at their distal terminals to monoclonal antibodies", Biochimica et Biophysica Acta, vol. 1234, no. 1, pp. 74-80, 1995.
82. K. Maruyama, T. Takizawa, N. Takahashi, T. Tagawa, K. Nagaike, and M. Iwatsuru, "Targeting efficiency of PEGimmunoliposomeconjugated antibodies at PEG terminals", Advanced Drug Delivery Reviews, vol. 24, no. 2-3, pp. 235-242, 1997.
83. G. Blume, G. Cevc, M. D. J. A. Crommelin, I. A. J. M. Bakker-Woudenberg, C. Kluft, and G. Storm, "Specific targeting with poly (ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times", Biochimica et Biophysica Acta-Biomembranes, vol. 1149, no. 1, pp. 180-184, 1993.
84. F. Zeng, H. Lee, and C. Allen, "Epidermal growth factorconjugated poly (ethylene glycol)-block-poly (δ-valerolactone) copolymer micelles for targeted delivery of chemotherapeutics", Bioconjugate Chemistry, vol. 17, no. 2, pp. 399-409, 2006.
85. 3 3 monoclonal antibody for highly efficient cancer cell targeting", Nanotechnology, vol. 20, no. 10, Article ID 105102, 2009.
86. B. Zhang, Q. Chen, H. Tang et al., "Characterization of and biomolecule immobilization on the biocompatiblemulti-walled carbon nanotubes generated by functionalizationwith polyamidoamine dendrimers", Colloids and Surfaces B: Biointerfaces, vol. 80, no. 1, pp. 18-25, 2010.
87. T. Dvir, M. Bauer, A. Schroeder et al., "Nanoparticles targeting the infarcted heart", Nano Letters, vol. 11, no. 10, pp. 4411-4414, 2011.
88. H.-T. Chou, T.-P. Wang, C.-Y. Lee, N.-H. Tai, and H.-Y. Chang, "Photothermal effects of multi-walled carbon nanotubes on the viability of BT-474 cancer cells", Materials Science and Engineering C, vol. 33, no. 2, pp. 989-995, 2013.
89. S.-J. Chiu, N. T. Ueno, and R. J. Lee, "Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine", Journal of Controlled Release, vol. 97, no. 2, pp. 357-369, 2004.
90. F. J. Martin and D. Papahadjopoulos, "Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting", The Journal of Biological Chemistry, vol. 257, no. 1, pp. 286-288, 1982.
91. D. Kirpotin, J. W. Park, K. Hong et al., "Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro", Biochemistry, vol. 36, no. 1, pp. 66-75, 1997.
92. T. M. Allen, E. Brandeis, C. B. Hansen, G. Y. Kao, and S. Zalipsky, "A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells", Biochimica et Biophysica Acta - Biomembranes, vol. 1237, no. 2, pp. 99-108, 1995.
93. C. B. Hansen, G. Y. Kao, E. H. Moase, S. Zalipsky, and T. M. Allen, "Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures", Biochimica et Biophysica Acta-Biomembranes, vol. 1239, no. 2, pp. 133-144, 1995.
94. S. Zalipsky, M. Newman, P. Bhagya, and C. M. Woodle, "Model ligands linked to the polymer-chains on liposomal surfaces: application of a new functionalized polyethylene glycol-lipid conjugate", PolymericMaterials: Science and Engineering, vol. 67, pp. 519-520, 1993.
95. J. W. Park, K. Hong, P. Carter et al., "Development of antip185HER2 immunoliposomes for cancer therapy", Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 5, pp. 1327-1331, 1995.
96. J. Ren, S. Shen, D. Wang et al., "The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multiwalled carbon nanotubes modified with angiopep-2", Biomaterials, vol. 33, no. 11, pp. 3324-3333, 2012.
97. M. G. Anhorn, S. Wagner, J. Kreuter, K. Langer, and H. Von Briesen, "Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles", Bioconjugate Chemistry, vol. 19, no. 12, pp. 2321-2331, 2008.
98. M. E. Gindy, S. Ji, T. R. Hoye, A. Z. Panagiotopoulos, and R. K. Prud'homme, "Preparation of poly (ethylene glycol) protected nanoparticles with variable bioconjugate ligand density", Biomacromolecules, vol. 9, no. 10, pp. 2705-2711, 2008.
99. O. C. Farokhzad, S. Jon, A. Khademhosseini, T.-N. T. Tran, D. A. La Van, and R. Langer, "Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells", Cancer Research, vol. 64, no. 21, pp. 7668-7672, 2004.
100. Z. Xiao, E. Levy-Nissenbaum, F. Alexis et al., "Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection", ACS Nano, vol. 61, no. 1, pp. 696-704, 2012.
101. Y. J. Lu, K. C. Wei, C. C. M. Ma, S. Y. Yang, and J. P. Chen, "Dual targeted delivery of doxorubicin to cancer cells using folateconjugated magnetic multi-walled carbon nanotubes", Colloids and Surfaces B: Biointerfaces, vol. 89, no. 1, pp. 1-9, 2012.
102. F. J. Martin, W. L. Hubbell, and D. Papahadjopoulos, "Immunospecific targeting of liposomes to cells: a novel and efficient method for covalent attachment of Fab' fragments via disulfide bonds", Biochemistry, vol. 20, no. 14, pp. 4229-4238, 1981.
103. V. O. Ivanov, S. N. Preobrazhensky, V. P. Tsibulsky, V. R. Babaev, V. S. Repin, and V. N. Smirnov, "Liposome uptake by cultured macrophages mediated by modified low-density lipoproteins", Biochimica et Biophysica Acta, vol. 846, no. 1, pp. 76-84, 1985.
104. M. S. Shaik, N. Kanikkannan, and M. Singh, "Conjugation of anti-My9 antibody to stealth monensin liposomes and the effect of conjugated liposomes on the cytotoxicity of immunotoxin", Journal of Controlled Release, vol. 76, no. 3, pp. 285-295, 2001.
105. M. Talelli, S. Oliveira, C. J. F. Rijcken et al., "Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy", Biomaterials, vol. 34, no. 4, pp. 1255-1260, 2013.
106. D. E. L. De Menezes, L. M. Pilarski, and T. M. Allen, "In vitro and in vivo targeting of immunoliposomal doxorubicin to human Bcell lymphoma", Cancer Research, vol. 58, no. 15, pp. 3320-3330, 1998.
107. M. M. Chua, S. T. Fan, and F. Karush, "Attachment of immunoglobulin to liposomal membrane via protein carbohydrate", Biochimica et Biophysica Acta, vol. 800, no. 3, pp. 291-300, 1984.
108. S. M. Chamow, T. P. Kogan, D. H. Peers, R. C. Hastings, R. A. Byrn, and A. Ashkenazi, "Conjugation of soluble CD4 without loss of biological activity via a novel carbohydrate-directed cross-linking reagent", The Journal of Biological Chemistry, vol. 267, no. 22, pp. 15916-15922, 1992.
109. J. A. Harding, C. M. Engbers, M. S. Newman, N. I. Goldstein, and S. Zalipsky, "Immunogenicity and pharmacokinetic attributes of poly (ethylene glycol)-grafted immunoliposomes", Biochimica et Biophysica Acta-Biomembranes, vol. 1327, no. 2, pp. 181-192, 1997.
110. M. Shi, J. H. Wosnick, K. Ho, A. Keating, and M. S. Shoichet, "Immuno-polymeric nanoparticles by Diels-Alder chemistry", Angewandte Chemie, vol. 46, no. 32, pp. 6126-6131, 2007.
111. A. D. De Araújo, J. M. Palomo, J. Cramer et al., "Diels-Alder ligation and surface immobilization of proteins", Angewandte Chemie International Edition, vol. 45, no. 2, pp. 296-301, 2005.
112. V. Marchan, S. Ortega, D. Pulido, E. Pedroso, and A. Grandas, "Diels-Alder cycloadditions in water for the straightforward preparation of peptide-oligonucleotide conjugates", Nucleic Acids Research, vol. 34, no. 3, p. e24, 2006.
113. H. C. Kolb, M. G. Finn, and K. B. Sharpless, "Click chemistry: diverse chemical function from a few good reactions", Angewandte Chemie International Edition, vol. 40, no. 11, pp. 2004-2021, 2001.
114. C. D. Hein, X.-M. Liu, and D. Wang, "Click chemistry, a powerful tool for pharmaceutical sciences", Pharmaceutical Research, vol. 25, no. 10, pp. 2216-2230, 2008.
115. B. Jeong, Y. H. Bae, D. S. Lee, and S. W. Kim, "Biodegradable block copolymers as injectable drug-delivery systems", Nature, vol. 388, no. 6645, pp. 860-862, 1997.
116. F. S. Hassane, B. Frisch, and F. Schuber, "Targeted liposomes: convenient coupling of ligands to preformed vesicles using "click chemistry"", Bioconjugate Chemistry, vol. 17, no. 3, pp. 849-854, 2006.
117. P. De, S. R. Gondi, and B. S. Sumerlin, "Folate-conjugated thermoresponsive block copolymers: highly efficient conjugation and solution self-assembly", Biomacromolecules, vol. 9, no. 3, pp. 1064-1070, 2008.
118. J. Lu, M. Shi, and M. S. Shoichet, "Click chemistry functionalized polymeric nanoparticles target corneal epithelial cells through RGD-cell surface receptors", Bioconjugate Chemistry, vol. 20, no. 1, pp. 87-94, 2009.
119. R. R. Sawant and V. P. Torchilin, "Challenges in development of targeted liposomal therapeutics", The AAPS Journal, vol. 14, no. 2, pp. 303-315, 2012.
120. H. Zhang, Y. Ma, and X.-L. Sun, "Chemically-selective surface glyco-functionalization of liposomes through Staudinger ligation", Chemical Communications, no. 21, pp. 3032-3034, 2009.
121. M.-Q. Gu, X.-B. Yuan, C.-S. Kang et al., "Surface biofunctionalization of PLA nanoparticles through amphiphilic polysaccharide coating and ligand coupling: evaluation of biofunctionalization and drug releasing behavior", Carbohydrate Polymers, vol. 67, no. 3, pp. 417-426, 2007.
122. D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, and R. Langer, "Nanocarriers as an emerging platform for cancer therapy", Nature Nanotechnology, vol. 2, no. 12, pp. 751-760, 2007.
123. B. S. Wong, S. L. Yoong, A. Jagusiak et al., "Carbon nanotubes for delivery of small molecule drugs", Advanced Drug Delivery Reviews, vol. 65, no. 15, pp. 1964-2015, 2013.
124. R. Sinha, G. J. Kim, S. Nie, and D. M. Shin, "Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery", Molecular CancerTherapeutics, vol. 5, no. 8, pp. 1909-1917, 2006.
125. V. Torchilin, "Multifunctional and stimuli-sensitive pharmaceutical nanocarriers", European Journal of Pharmaceutics and Biopharmaceutics, vol. 71, no. 3, pp. 431-444, 2009.
126. D. R. Khan, "The use of nanocarriers for drug delivery in cancer therapy", Journal of Cancer Science and Therapy, vol. 2, no. 3, pp. 58-62, 2010.
127. H. S. Yoo, K. H. Lee, J. E. Oh, and T. G. Park, "Invitroand invivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates", Journal of Controlled Release, vol. 68, no. 3, pp. 419-431, 2000.
128. H. S. Yoo, J. E. Oh, K. H. Lee, and T. G. Park, "Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release", Pharmaceutical Research, vol. 16, no. 7, pp. 1114-1118, 1999.
129. T. L. Moore, J. E. Pitzer, R. Podila et al., "Multifunctional polymer-coated carbon nanotubes for safe drug delivery", Particle and Particle Systems Characterization, vol. 30, no. 4, pp. 365-373, 2013.
130. L. Juillerat-Jeanneret, "The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?" Drug Discovery Today, vol. 13, no. 23-24, pp. 1099-1106, 2008.
131. S. K. Vashist, D. Zheng, K. Al-Rubeaan, J. H. T. Luong, and F.-S. Sheu, "Advances in carbon nanotube based electrochemical sensors for bioanalytical applications", Biotechnology Advances, vol. 29, no. 2, pp. 169-188, 2011.
132. R. Marega and D. Bonifazi, "Filling carbon nanotubes for nanobiotechnological applications", New Journal of Chemistry, vol. 38, no. 1, pp. 22-27, 2014.
133. M. Yudasaka, K. Ajima, K. Suenaga, T. Ichihashi, A. Hashimoto, and S. Iijima, "Nano-extraction and nano-condensation for C60 incorporation into single-wall carbon nanotubes in liquid phases", Chemical Physics Letters, vol. 380, no. 1-2, pp. 42-46, 2003.
134. C. Tripisciano, K. Kraemer, A. Taylor, and E. Borowiak-Palen, "Single-wall carbon nanotubes based anticancer drug delivery system", Chemical Physics Letters, vol. 478, no. 4-6, pp. 200-205, 2009.
135. C. Tripisciano, S. Costa, R. J. Kalenczuk, and E. Borowiak-Palen, "Cisplatin filledmultiwalled carbon nanotubes-a novelmolecular hybrid of anticancer drug container", European Physical Journal B, vol. 75, no. 2, pp. 141-146, 2010.
136. J. Li, S. Q. Yap, S. L. Yoong et al., "Carbon nanotube bottles for incorporation, release and enhanced cytotoxic effect of cisplatin", Carbon, vol. 50, no. 4, pp. 1625-1634, 2012.
137. L. Sui, T. Yang, P. Gao et al., "Incorporation of cisplatin into PEG-wrapped ultrapurified large-inner-diameterMWCNTs for enhanced loading efficiency and release profile", International Journal of Pharmaceutics, vol. 471, no. 1-2, pp. 157-165, 2014.
138. E. C. Gryparis, M. Hatziapostolou, E. Papadimitriou, and K. Avgoustakis, "Anticancer activity of cisplatin-loaded PLGAmPEG nanoparticles on LNCaP prostate cancer cells", European Journal of Pharmaceutics and Biopharmaceutics, vol. 67, no. 1, pp. 1-8, 2007.
139. N. Nishiyama and K. Kataoka, "Preparation and characterization of size-controlled polymeric micelle containing cisdichlorodiammineplatinum (II) in the core", Journal of Controlled Release, vol. 74, no. 1-3, pp. 83-94, 2001.
140. Y. Mizumura, Y. Matsumura, T. Hamaguchi et al., "Cisplatinincorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity", Japanese Journal of Cancer Research, vol. 92, no. 3, pp. 328-336, 2001.
141. A. Schroeder, R. Honen, K. Turjeman, A. Gabizon, J. Kost, and Y. Barenholz, "Ultrasound triggered release of cisplatin from liposomes inmurine tumors", Journal of Controlled Release, vol. 137, no. 1, pp. 63-68, 20
142. M. S. Newman, G. T. Colbern, P. K. Working, C. Engbers, and M. A. Amantea, "Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumorbearing mice", Cancer Chemotherapy and Pharmacology, vol. 43, no. 1, pp. 1-7, 1999.
143. K. Ajima, M. Yudasaka, T. Murakami, A. Maigné, K. Shiba, and S. Iijima, "Carbon nanohorns as anticancer drug carriers", Molecular Pharmaceutics, vol. 2, no. 6, pp. 475-480, 2005.
144. K. Ajima, T. Murakami, Y. Mizoguchi et al., "Enhancement of in vivo anticancer effects of cisplatin by incorporation inside single-wall carbon nanohorns", ACS Nano, vol. 2, no. 10, pp. 2057-2064, 2008.
145. S. Hampel, D. Kunze, D. Haase et al., "Carbon nanotubes filled with a chemotherapeutic agent: a nanocarrier mediates inhibition of tumor cell growth", Nanomedicine, vol. 3, no. 2, pp. 175-182, 2008.
146. 3 3 integrintargeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt (IV) prodrug", ACS Nano, vol. 6, no. 5, pp. 4530-4539, 2012.
147. S. Mitra, U. Gaur, P. C. Ghosh, and A. N. Maitra, "Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier", Journal of Controlled Release, vol. 74, no. 1-3, pp. 317-323, 2001.
148. F. Lince, S. Bolognesi, B. Stella, D. L. Marchisio, and F. Dosio, "Preparation of polymer nanoparticles loaded with doxorubicin for controlled drug delivery", Chemical Engineering Research and Design, vol. 89, no. 11, pp. 2410-2419, 2011.
149. H. Park, J. Yang, J. Lee, S. Haam, I.-H. Choi, and K.-H. Yoo, "Multifunctional nanoparticles for combined doxorubicin and photothermal treatments", ACS Nano, vol. 3, no. 10, pp. 2919-2926, 2009.
150. Y. Matsumura, M. Gotoh, K. Muro et al., "Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer", Annals of Oncology, vol. 15, no. 3, pp. 517-525, 2004.
151. A. A. Gabizon, "Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new formof chemotherapy", Cancer Investigation, vol. 19, no. 4, pp. 424-436, 2001.
152. K. Kataoka, T. Matsumoto, M. Yokoyama et al., "Doxorubicinloaded poly (ethylene glycol)-poly (β-benzyl-L-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance", Journal of Controlled Release, vol. 64, no. 1-3, pp. 143-153, 2000.
153. F. Perche, N. R. Patel, and V. P. Torchilin, "Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model", Journal of Controlled Release, vol. 164, no. 1, pp. 95-102, 2012.
154. A. B. Ebrahim Attia, C. Yang, J. P. K. Tan et al., "The effect of kinetic stability on biodistribution and anti-tumor efficacy of drug-loaded biodegradable polymeric micelles", Biomaterials, vol. 34, no. 12, pp. 3132-3140, 2013.
155. A. Cambón, A. Rey-Rico, D. Mistry et al., "Doxorubicin-loaded micelles of reverse poly (butylene oxide)-poly (ethylene oxide) - poly (butylene oxide) block copolymers as efficient 'active' chemotherapeutic agents", International Journal of Pharmaceutics, vol. 445, no. 1-2, pp. 47-57, 2013.
156. J. M. Koziara, P. R. Lockman, D. D. Allen, and R. J. Mumper, "Paclitaxel nanoparticles for the potential treatment of brain tumors", Journal of Controlled Release, vol. 99, no. 2, pp. 259-269, 2004.
157. G. Ruan and S.-S. Feng, "Preparation and characterization of poly (lactic acid)-poly (ethylene glycol)-poly (lactic acid) (PLAPEG-PLA) microspheres for controlled release of paclitaxel", Biomaterials, vol. 24, no. 27, pp. 5037-5044, 2003.
158. C. Fonseca, S. Simões, and R. Gaspar, "Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity", Journal of Controlled Release, vol. 83, no. 2, pp. 273-286, 2002.
159. J. M. Chan, J. W. Rhee, C. L. Drum et al., "In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipidpolymeric nanoparticles", Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 48, pp. 19347-19352, 2011.
160. T. Hamaguchi, K. Kato, H. Yasui et al., "A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation", British Journal of Cancer, vol. 97, no. 2, pp. 170-176, 2007.
161. T.-Y. Kim, D.-W. Kim, J.-Y. Chung et al., "Phase I and pharmacokinetic study of Genexol-PM, a Cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies", Clinical Cancer Research, vol. 10, no. 11, pp. 3708-3716, 2004.
162. F. Wang, Y. Chen, D. Zhang et al., "Folate-mediated targeted and intracellular delivery of paclitaxel using a novel deoxycholic acid-O-carboxymethylated chitosan-folic acid micelles", International Journal of Nanomedicine, vol. 7, pp. 325-337, 2012.
163. Z. Liu, J. T. Robinson, S. M. Tabakman, K. Yang, and H. Dai, "Carbon materials for drug delivery and cancer therapy", Materials Today, vol. 14, no. 7-8, pp. 316-323, 2011.
164. K. R. West and S. Otto, "Reversible covalent chemistry in drug delivery", Current Drug Discovery Technologies, vol. 2, no. 3, pp. 123-160, 2005.
165. C. Li, R. A. Newman, Q.-P. Wu et al., "Biodistribution of paclitaxel and poly (L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor", Cancer Chemotherapy and Pharmacology, vol. 46, no. 5, pp. 416-422, 2000.
166. L. Milas, K. A. Mason, N. Hunter, C. Li, and S. Wallace, "Poly (L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability", International Journal of Radiation Oncology Biology Physics, vol. 55, no. 3, pp. 707-712, 2003.
167. T. Etrych, T. Mrkvan, P. Chytil, Č. Koňák, B. Říhová, and K. Ulbrich, "N-(2-hydroxypropyl) methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin. I. New synthesis, physicochemical characterization and preliminary biological evaluation", Journal of Applied Polymer Science, vol. 109, no. 5, pp. 3050-3061, 2008.
168. M. Hrubý, Č. Koňák, and K. Ulbrich, "Polymeric micellar pH-sensitive drug delivery system for doxorubicin", Journal of Controlled Release, vol. 103, no. 1, pp. 137-148, 2005.
169. D. Vetvicka, M. Hruby, O. Hovorka et al., "Biological evaluation of polymeric micelles with covalently bound doxorubicin", Bioconjugate Chemistry, vol. 20, no. 11, pp. 2090-2097, 2009.
170. C. Liu, F. Liu, L. Feng, M. Li, J. Zhang, and N. Zhang, "The targeted co-delivery of DNA and doxorubicin to tumor cells via multifunctional PEI-PEG based nanoparticles", Biomaterials, vol. 34, no. 10, pp. 2547-2564, 2013.
171. H. S. Yoo, E. A. Lee, and T. G. Park, "Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages", Journal of Controlled Release, vol. 82, no. 1, pp. 17-27, 2002.
172. S. Aryal, C.-M. J. Hu, and L. Zhang, "Polymer-cisplatin conjugate nanoparticles for acid-responsive drug delivery", ACS Nano, vol. 4, no. 1, pp. 251-258, 2010.
173. E. Tsai, "Dendrimer encapsulated nanoparticles: vehicles for drug delivery, with an emphasis on PAMAM dendrimers", Cosmos, vol. 8, pp. 1-16, 2011.
174. P. C. A. Rodrigues, K. Scheuermann, C. Stockmar et al., "Synthesis and in vitro efficacy of acid-sensitive poly (ethylene glycol) paclitaxel conjugates", Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 3, pp. 355-360, 2003.
175. R. P. Feazell, N. Nakayama-Ratchford, H. Dai, and S. J. Lippard, "Soluble single-walled carbon nanotubes as longboat delivery systems for platinum (IV) anticancer drug design", Journal of the American Chemical Society, vol. 129, no. 27, pp. 8438-8439, 2007.
176. Y.-Z. Zhao, C.-Z. Sun, C.-T. Lu et al., "Characterization and anti-tumor activity of chemical conjugation of doxorubicin in polymeric micelles (DOX-P) in vitro", Cancer Letters, vol. 311, no. 2, pp. 187-194, 2011.
177. P.-S. Lai, P.-J. Lou, C.-L. Peng et al., "Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy", Journal of Controlled Release, vol. 122, no. 1, pp. 39-46, 2007.
178. J. Chen, S. Chen, X. Zhao, L. V. Kuznetsova, S. S. Wong, and I. Ojima, "Functionalized single-walled carbon nanotubes as rationally designed vehicles for tumor-targeted drug delivery", Journal of the American Chemical Society, vol. 130, no. 49, pp. 16778-16785, 2008.
179. L. Niu, L. Meng, and Q. Lu, "Folate-conjugated PEG on single walled carbon nanotubes for targeting delivery of doxorubicin to cancer cells", Macromolecular Bioscience, vol. 13, no. 6, pp. 735-744, 2013.
180. K. Kataoka, T. Matsumoto, M. Yokoyama et al., "Doxorubicinloaded poly (ethylene glycol)-poly (beta-benzyl-L-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance", Journal of Controlled Release, vol. 64, no. 1-3, pp. 143-153, 2000.
181. K. Greish, T. Sawa, J. Fang, T. Akaike, and H. Maeda, "SMAdoxorubicin, a new polymeric micellar drug for effective targeting to solid tumours", Journal of Controlled Release, vol. 97, no. 2, pp. 219-230, 2004.
182. H. Ali-Boucetta, K. T. Al-Jamal, D. McCarthy, M. Prato, A. Bianco, and K. Kostarelos, "Multiwalled carbon nanotubedoxorubicin supramolecular complexes for cancer therapeutics", Chemical Communications, vol. 8, no. 4, pp. 459-461, 2008.
183. E. Heister, V. Neves, C. Tîlmaciu et al., "Triple functionalisation of single-walled carbon nanotubes with doxorubicin, a monoclonal antibody, and a fluorescent marker for targeted cancer therapy", Carbon, vol. 47, no. 9, pp. 2152-2160, 2009.
184. X. Zhang, L. Meng, Q. Lu, Z. Fei, and P. J. Dyson, "Targeted delivery and controlled release of doxorubicin to cancer cells usingmodified singlewall carbon nanotubes", Biomaterials, vol. 30, no. 30, pp. 6041-6047, 2009.
185. Z. Liu, X. Sun, N. Nakayama-Ratchford, and H. Dai, "Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery", ACS Nano, vol. 1, no. 1, pp. 50-56, 2007.
186. A. Di Crescenzo, D. Velluto, J. A. Hubbell, and A. Fontana, "Biocompatible dispersions of carbon nanotubes: a potential tool for intracellular transport of anticancer drugs", Nanoscale, vol. 3, no. 3, pp. 925-928, 2011.
187. Z. Tian, Y. Shi, M. Yin, H. Shen, and N. Jia, "Functionalizedmultiwalled carbon nanotubes-anticancer drug carriers: synthesis, targeting ability and antitumor activity", Nano Biomedicine and Engineering, vol. 3, no. 3, pp. 157-162, 2011.
188. A. Duma, M. Prodana, and I. Demetrescu, "Cisplatin functionalization of multiwall carbon nanotubes", UPB Scientific Bulletin, Series B: Chemistry and Materials Science, vol. 76, no. 1, pp. 49-58, 2014.
189. A. Barroug, L. T. Kuhn, L. C. Gerstenfeld, and M. J. Glimcher, "Interactions of cisplatin with calcium phosphate nanoparticles: in vitro controlled adsorption and release", Journal of Orthopaedic Research, vol. 22, no. 4, pp. 703-708, 2004.
190. M. Arlt, D. Haase, S. Hampel et al., "Delivery of carboplatin by carbon-based nanocontainers mediates increased cancer cell death", Nanotechnology, vol. 21, no. 33, Article ID 335101, 2010.
191. Y. Wang, S.-T. Yang, Y. Wang, Y. Liu, and H. Wang, "Adsorption and desorption of doxorubicin on oxidized carbon nanotubes", Colloids and Surfaces B: Biointerfaces, vol. 97, pp. 62-69, 2012.
192. Y.-I. Jeong, S.-T. Kim, S.-G. Jin et al., "Cisplatin-lncorporated hyaluronic acid nanoparticles based on ion-complex formation", Journal of Pharmaceutical Sciences, vol. 97, no. 3, pp. 1268-1276, 2008.
193. T. K. Bronich, A. Nehls, A. Eisenberg, V. A. Kabanov, and A. V. Kabanov, "Novel drug delivery systems based on the complexes of block ionomers and surfactants of opposite charge", Colloids and Surfaces B: Biointerfaces, vol. 16, no. 1-4, pp. 243-251, 1999.
194. G. Pastorin, W. Wu, S. Wieckowski et al., "Double functionalisation of carbon nanotubes for multimodal drug delivery", Chemical Communications, no. 11, pp. 1182-1184, 2006.
195. R. Li, R. Wu, L. Zhao, M. Wu, L. Yang, and H. Zou, "Pglycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells", ACS Nano, vol. 4, no. 3, pp. 1399-1408, 2010.
196. L. Zhang, A. F. Radovic-Moreno, F. Alexis et al., "Co-delivery of hydrophobic and hydrophilic drugsfrom nanoparticle-aptamer bioconjugates", ChemMedChem, vol. 2, no. 9, pp. 1268-1271, 2007.
197. K. Werengowska-Ciećwierz, M. Wis̈niewski, A. P. Terzyk et al., "Nanotube-mediated efficiency of cisplatin anticancer therapy", Carbon, vol. 70, pp. 46-58, 2014.
198. N. Lodhi, N. K. Mehra, and N. K. Jain, "Development and characterization of dexamethasonemesylate anchored onmulti walled carbon nanotubes", Journal of Drug Targeting, vol. 21, no. 1, pp. 67-76, 2013.
199. J. Shi, Z. Xiao, N. Kamaly, and O. C. Farokhzad, "Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation", Accounts of Chemical Research, vol. 44, no. 10, pp. 1123-1134, 2011.